ClinicalTrials.gg
CompletedNCT00411450PRECEPTUpdated Feb 15, 2016Results posted

Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment

A Phase 2 interventional study of Panitumumab and FOLFIRI in Colon Cancer, Colorectal Cancer and Rectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-15.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing panitumumab in Colonic Neoplasms — 1 open to participants now, 2 under way, 1 of them phase 3. Panitumumab · Colonic Neoplasms.

Enrollment
11th of 21
116 · median 116
Started
2006
with 2 others
Phase 2
15 of 22
none open now
Registered
6th of 22
by date
Lead sponsor
6 of 22
Amgen

Among the 22 studies testing panitumumab in Colonic Neoplasms, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2006, is one of 15 in phase 2, and was the 6th registered.

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

1 of the 22 studies testing panitumumab in Colonic Neoplasms is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing panitumumab in Colonic Neoplasms, or all of them as a file.
02

Study summary

The primary objective is to estimate the effect of the human homolog of the Kirsten rat sarcoma-2 virus oncogene (KRAS) mutation status (wild type versus mutant) from tumor tissue on efficacy endpoints in patients with metastatic colorectal cancer (mCRC) receiving second-line chemotherapy with panitumumab after failing first-line treatment.

03

Conditions studied

  • Colon Cancer
  • Colorectal Cancer
  • Rectal Cancer
  • Cancer
  • Metastatic Cancer
  • Metastatic Colorectal Cancer
  • Oncology

Keywords

  • k-ras
  • biomarker
  • colorectal
  • colon
  • rectal
  • FOLFOX
  • FOLFIRI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of adenocarcinoma of the colon or rectum
  • Available paraffin-embedded tumor tissue
  • Failure of treatment containing fluoropyrimidine and oxaliplatin based chemotherapy with bevacizumab for mCRC
  • Adequate hematologic, renal, hepatic and metabolic function

Exclusion criteria

Exclusion Criteria:

  • Radiotherapy ≤ 2 weeks prior to Day 1 of Cycle 1
  • Unresolved toxicity(ies) from prior anti cancer therapy that, in the opinion of the investigator, precludes the subject from study enrollment
  • Prior irinotecan therapy, anti epidermal growth factor receptor (EGFr) therapy, or vaccine for the treatment of mCRC
  • enzyme inducers, inhibitors, and substrates (eg, phenytoin, phenobarbital, carbamazepine, ketoconazole, rifampin, rifabutin, and St. John's Wort) ≤ 2 weeks prior to Day 1 of Cycle 1
  • Infection requiring systemic anti infectives completed ≤ 2 weeks prior to Day 1 of Cycle 1
  • cardiovascular disease
  • History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis)
  • Pulmonary embolism, deep vein thrombosis, or other significant thromboembolic event ≤ 8 weeks prior to Day 1 of Cycle 1
  • Any significant bleeding ≤ 6 weeks prior to Day 1 of Cycle 1, per the investigator's judgement
  • Gastroduodenal ulcer(s) determined by endoscopy to be active or uncontrolled gastrointestinal ulcer ≤ 4 weeks prior to Day1 of Cycle 1
  • Any co-morbid disease or condition that could increase the risk of toxicity (eg, dihydropyrimidine deficiency, significant ascites, or pleural effusion)
  • Major surgery (requiring general anesthesia), open , or significant traumatic injury ≤ 4 weeks prior to Day1 of Cycle 1. Subjects must have recovered from surgery and have no significant complications
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Panitumumab plus FOLFIRI

    Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until disease progression, intolerability, death, or study withdrawal.

    Biological: Panitumumab · Drug: FOLFIRI

Interventions

  • BiologicalPanitumumab

    Administered by intravenous infusion

    Also known as: Vectibix

  • DrugFOLFIRI

    Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate at Weeks 17 and 25

    Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments were based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. A complete or partial response was confirmed no less than 4 weeks after the criteria for response were first met. Participants with no radiographic tumor assessment(s) at Week 17 or 25 were considered non-responders. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions (defined as a ≥ 25% increase in lesion size) and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions.

    Time frame: Week 17 and Week 25

  2. Best Response During Second-Line Treatment

    Objective response rate is defined as the percentage of participants with a best response of complete response or partial response based on investigator review of scans using modified RECIST criteria. A complete or partial response was confirmed no less than 4 weeks after the criteria for response were first met. Participants with no post-baseline radiographic tumor assessment(s) were considered non-responders. CR: disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions (defined as a ≥ 25% increase in lesion size) and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or PD and no new lesions.

    Time frame: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.

  3. Progression-free Survival Rate at Weeks 17 and 25

    The progression-free survival rate is defined as the Kaplan-Meier (KM) estimator of progression-free survival at Week 17 and Week 25 reported as the probability of being event (disease progression or death)-free. Tumor assessments were evaluated by the investigator according to modified RECIST criteria. PD: At least a 20% increase in the size of target lesions since the treatment started or at least a 25% increase in the size of non-target lesions and the lesion(s) measure ≥ 10 mm, or the appearance of any new lesions. Participants who withdraw from the study prior to completion of Week 17 or 25 radiographic tumor assessments were censored at the last evaluable tumor assessment.

    Time frame: Week 17 and Week 25

  4. Progression-free Survival Time

    Progression-free survival time was defined as the time from Study Day 1 to the date of disease progression (based on investigator assessment) or the date of death due to any cause. Participants who terminated from the study early (eg, prior to disease progression due to fully withdrawn informed consent) were censored at their last tumor assessment.

    Time frame: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.

  5. Disease Control Rate at Weeks 17 and 25

    The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST criteria as assessed by the investigator. Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline.

    Time frame: Week 17 and Week 25

  6. Duration of Response

    Duration of response is defined as the time from the date of first response to the date of first progression of disease during second-line treatment (as evaluated by the investigator) or death (if the death was due to disease progression but not detected earlier) in the subset of participants who responded (CR or PR, as evaluated by the investigator). Duration of response was analyzed using Kaplan-Meier methods; participants who responded but did not progress while on study were censored at the date of last tumor assessment.

    Time frame: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.

  7. Overall Survival

    Overall survival is defined as as the number of days from Study Day 1 to the date of death due to any cause. Overall survival was analyzed using the Kaplan-Meier method; participants who were lost to follow-up or who had not died at the end of the study (52 weeks after the last participant was enrolled) were censored at the date of last contact.

    Time frame: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.

  8. Time to Treatment Failure

    Time to failure of second-line treatment is defined as the time from study Day 1 to the date of the earliest of the following events: end of second-line therapy due to any reason except for complete response and curative surgery; progressive disease; or death due to any cause. Time to treatment failure was analyzed using Kaplan-Meier methods; participants who did not discontinue second-line treatment or discontinue due to complete response or curative surgery, who were still alive, and who did not have disease progression were censored at the date of the last contact.

    Time frame: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.

  9. Time to Progression

    Time to progression is defined as the time from study Day 1 to the date of observed disease progression. Time to progression was analyzed using Kaplan-Meier methods; participants who did not have disease progression were censored at the date of last evaluable tumor assessment.

    Time frame: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.

  10. Time to Response

    Time to response of second-line treatment is defined as the time from study Day 1 to the date of first documentation of CR or PR, calculated for those participants with an objective tumor response of CR or PR.

    Time frame: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.

Secondary outcomes

  1. Number of Participants With Adverse Events

    The severity of adverse events (AEs) was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, except for panitumumab related skin toxicities, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. The relationship of each adverse event to the panitumumab and/or FOLFIRI regimen was assessed by the investigator. A serious adverse event was defined as an adverse event that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard.

    Time frame: From the first dose date to 30 days after the last dose date. The median time frame is 4.5 months.

  2. Number of Participants With Grade 4 Laboratory Toxicities

    Laboratory toxicities were graded according to CTCAE version 3.

    Time frame: From the first dose date to 30 days after the last dose date. The median time frame is 4.5 months.

  3. Number of Participants Who Developed Antibodies to Panitumumab

    The immunogenicity of panitumumab was evaluated using 2 different screening immunoassays for the detection of anti-panitumumab antibodies: an acid dissociation bridging enzyme-linked immunosorbent assay (ELISA; detecting high-affinity antibodies) and a Biacore® biosensor immunoassay (detecting both high and low-affinity antibodies). When either of the 2 screening assays yielded a positive result, that particular sample was subjected to an in vitro bioassay for the detection of neutralizing antibodies.

    Time frame: Prior to first dose and 28 days after the last dose of second-line treatment

07

Results

Posted Feb 15, 2016

Participant flow

This study was conducted at 56 sites in the United States. The first patient enrolled on 30 November 2006 and the last patient enrolled on 07 January 2008.

Participant flow — Overall Study
MilestonePanitumumab Plus FOLFIRI
Started116
Received treatment115
Completed113
Not completed3
Withdrew: Ongoing at time of data cut-off.3

Outcome measures

PrimaryObjective Response Rate at Weeks 17 and 25

Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments were based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. A complete or partial response was confirmed no less than 4 weeks after the criteria for response were first met. Participants with no radiographic tumor assessment(s) at Week 17 or 25 were considered non-responders. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions (defined as a ≥ 25% increase in lesion size) and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions.

Time frame:
Week 17 and Week 25
Reported as:
Number · percentage of participants
Objective Response Rate at Weeks 17 and 25
percentage of participantsWild-type KRASMutant KRAS
Week 1720 (10 to 30)14 (4 to 24)
Week 2522 (12 to 32)14 (4 to 24)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Difference: 6 · 95% CI -11 to 21Difference = Wild type - Mutant
  • Wild-type KRAS vs Mutant KRAS · Difference: 8 · 95% CI -9 to 23
SecondaryNumber of Participants With Adverse Events

The severity of adverse events (AEs) was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, except for panitumumab related skin toxicities, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. The relationship of each adverse event to the panitumumab and/or FOLFIRI regimen was assessed by the investigator. A serious adverse event was defined as an adverse event that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard.

Time frame:
From the first dose date to 30 days after the last dose date. The median time frame is 4.5 months.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsPanitumumab Plus FOLFIRI
Any adverse event115
Grade 3 or higher adverse event94
Panitumumab-related adverse events107
Chemotherapy-related adverse events112
≥ grade 3 panitumumab-related adverse events56
≥ grade 3 chemotherapy-related adverse events65
Serious adverse events46
Serious panitumumab-related adverse events15
Serious chemotherapy-related adverse events24
Life-threatening adverse events18
Ended second-line treatment due to adverse events18
Ended panitumumab due to adverse events20
Ended FOLFIRI due to adverse events28
Death due to adverse events8
Panitumumab infusion reactions2
Deaths during study71
PrimaryBest Response During Second-Line Treatment

Objective response rate is defined as the percentage of participants with a best response of complete response or partial response based on investigator review of scans using modified RECIST criteria. A complete or partial response was confirmed no less than 4 weeks after the criteria for response were first met. Participants with no post-baseline radiographic tumor assessment(s) were considered non-responders. CR: disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions (defined as a ≥ 25% increase in lesion size) and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or PD and no new lesions.

Time frame:
Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.
Reported as:
Number · percentage of participants
Best Response During Second-Line Treatment
percentage of participantsWild-type KRASMutant KRAS
Best Response During Second-Line Treatment23 (13 to 34)16 (5 to 27)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Difference: 7 · 95% CI -11 to 23Difference = Wild type - Mutant
PrimaryProgression-free Survival Rate at Weeks 17 and 25

The progression-free survival rate is defined as the Kaplan-Meier (KM) estimator of progression-free survival at Week 17 and Week 25 reported as the probability of being event (disease progression or death)-free. Tumor assessments were evaluated by the investigator according to modified RECIST criteria. PD: At least a 20% increase in the size of target lesions since the treatment started or at least a 25% increase in the size of non-target lesions and the lesion(s) measure ≥ 10 mm, or the appearance of any new lesions. Participants who withdraw from the study prior to completion of Week 17 or 25 radiographic tumor assessments were censored at the last evaluable tumor assessment.

Time frame:
Week 17 and Week 25
Reported as:
Number · percent probability
Progression-free Survival Rate at Weeks 17 and 25
percent probabilityWild-type KRASMutant KRAS
Week 1767 (54 to 77)55 (39 to 68)
Week 2552 (39 to 64)41 (27 to 55)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Difference: 12.5 · 95% CI -6.3 to 31.4Difference = Wild type - Mutant
  • Wild-type KRAS vs Mutant KRAS · Difference: 10.9 · 95% CI -8.4 to 30.2
PrimaryProgression-free Survival Time

Progression-free survival time was defined as the time from Study Day 1 to the date of disease progression (based on investigator assessment) or the date of death due to any cause. Participants who terminated from the study early (eg, prior to disease progression due to fully withdrawn informed consent) were censored at their last tumor assessment.

Time frame:
From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.
Reported as:
Median · weeks
Progression-free Survival Time
weeksWild-type KRASMutant KRAS
Progression-free Survival Time26 (19 to 33)19 (12 to 25)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Hazard ratio (hr): 0.8 · 95% CI 0.5 to 1.1Hazard ratio estimated from a Cox Proportional Hazards regression model with only KRAS effect (Wild type vs. Mutant).
PrimaryDisease Control Rate at Weeks 17 and 25

The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST criteria as assessed by the investigator. Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline.

Time frame:
Week 17 and Week 25
Reported as:
Number · percentage of participants
Disease Control Rate at Weeks 17 and 25
percentage of participantsWild-type KRASMutant KRAS
Week 1764 (52 to 76)58 (43 to 73)
Week 2564 (52 to 76)58 (43 to 73)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Difference: 6 · 95% CI -14 to 25Difference = Wild type - Mutant
  • Wild-type KRAS vs Mutant KRAS · Difference: 6 · 95% CI -14 to 25
PrimaryDuration of Response

Duration of response is defined as the time from the date of first response to the date of first progression of disease during second-line treatment (as evaluated by the investigator) or death (if the death was due to disease progression but not detected earlier) in the subset of participants who responded (CR or PR, as evaluated by the investigator). Duration of response was analyzed using Kaplan-Meier methods; participants who responded but did not progress while on study were censored at the date of last tumor assessment.

Time frame:
Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.
Reported as:
Median · weeks
Duration of Response
weeksWild-type KRASMutant KRAS
Duration of Response29 (21 to 39)23 (16 to 74)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Hazard ratio (hr): 0.7 · 95% CI 0.2 to 2.0Hazard ratio estimated from a Cox Proportional Hazards regression model with only KRAS effect (Wild type vs. Mutant).
PrimaryOverall Survival

Overall survival is defined as as the number of days from Study Day 1 to the date of death due to any cause. Overall survival was analyzed using the Kaplan-Meier method; participants who were lost to follow-up or who had not died at the end of the study (52 weeks after the last participant was enrolled) were censored at the date of last contact.

Time frame:
From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.
Reported as:
Median · weeks
Overall Survival
weeksWild-type KRASMutant KRAS
Overall Survival50 (39 to 76)31 (23 to 47)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Hazard ratio (hr): 0.6 · 95% CI 0.4 to 0.9Hazard ratio estimated from a Cox Proportional Hazards regression model with only KRAS effect (Wild type vs. Mutant).
PrimaryTime to Treatment Failure

Time to failure of second-line treatment is defined as the time from study Day 1 to the date of the earliest of the following events: end of second-line therapy due to any reason except for complete response and curative surgery; progressive disease; or death due to any cause. Time to treatment failure was analyzed using Kaplan-Meier methods; participants who did not discontinue second-line treatment or discontinue due to complete response or curative surgery, who were still alive, and who did not have disease progression were censored at the date of the last contact.

Time frame:
Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.
Reported as:
Median · weeks
Time to Treatment Failure
weeksWild-type KRASMutant KRAS
Time to Treatment Failure19 (14 to 25)15 (8 to 19)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Hazard ratio (hr): 0.7 · 95% CI 0.5 to 1.1Hazard ratio estimated from a Cox Proportional Hazards regression model with only KRAS effect (Wild type vs. Mutant).
PrimaryTime to Progression

Time to progression is defined as the time from study Day 1 to the date of observed disease progression. Time to progression was analyzed using Kaplan-Meier methods; participants who did not have disease progression were censored at the date of last evaluable tumor assessment.

Time frame:
From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.
Reported as:
Median · weeks
Time to Progression
weeksWild-type KRASMutant KRAS
Time to Progression26 (16 to 34)17 (15 to 25)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Hazard ratio (hr): 0.8 · 95% CI 0.5 to 1.2Hazard ratio estimated from a Cox Proportional Hazards regression model with only KRAS effect (Wild type vs. Mutant).
PrimaryTime to Response

Time to response of second-line treatment is defined as the time from study Day 1 to the date of first documentation of CR or PR, calculated for those participants with an objective tumor response of CR or PR.

Time frame:
Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.
Reported as:
Median · weeks
Time to Response
weeksWild-type KRASMutant KRAS
Time to Response9.1 (6.9 to 32.3)9.3 (7.0 to 35.6)
SecondaryNumber of Participants With Grade 4 Laboratory Toxicities

Laboratory toxicities were graded according to CTCAE version 3.

Time frame:
From the first dose date to 30 days after the last dose date. The median time frame is 4.5 months.
Reported as:
Number · participants
Number of Participants With Grade 4 Laboratory Toxicities
participantsPanitumumab Plus FOLFIRI
Anemia1
Neutropenia4
Hypomagnesaemia8
Hypokalemia1
Hypocalcaemia3
Hyperbilirubinaemia1
SecondaryNumber of Participants Who Developed Antibodies to Panitumumab

The immunogenicity of panitumumab was evaluated using 2 different screening immunoassays for the detection of anti-panitumumab antibodies: an acid dissociation bridging enzyme-linked immunosorbent assay (ELISA; detecting high-affinity antibodies) and a Biacore® biosensor immunoassay (detecting both high and low-affinity antibodies). When either of the 2 screening assays yielded a positive result, that particular sample was subjected to an in vitro bioassay for the detection of neutralizing antibodies.

Time frame:
Prior to first dose and 28 days after the last dose of second-line treatment
Reported as:
Number · participants
Number of Participants Who Developed Antibodies to Panitumumab
participantsPanitumumab Plus FOLFIRI
Binding antibody positive1
Neutralizing antibody positive0

Adverse events

Collected over The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 4.5 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab + FOLFIRI—46/115 (40%)114/115 (99.1%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventPanitumumab + FOLFIRI
DehydrationMetabolism and nutrition disorders12/115
PyrexiaGeneral disorders6/115
NeutropeniaBlood and lymphatic system disorders4/115
Mucosal inflammationGeneral disorders4/115
SepsisInfections and infestations4/115
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/115
Deep vein thrombosisVascular disorders4/115
DiarrhoeaGastrointestinal disorders3/115
AstheniaGeneral disorders3/115
SyncopeNervous system disorders3/115
Most frequent other events
Showing 10 of 58
Most frequent other events
EventPanitumumab + FOLFIRI
DiarrhoeaGastrointestinal disorders85/115
NauseaGastrointestinal disorders64/115
FatigueGeneral disorders61/115
RashSkin and subcutaneous tissue disorders60/115
Dermatitis acneiformSkin and subcutaneous tissue disorders44/115
Mucosal inflammationGeneral disorders38/115
AnorexiaMetabolism and nutrition disorders38/115
VomitingGastrointestinal disorders34/115
NeutropeniaBlood and lymphatic system disorders33/115
StomatitisGastrointestinal disorders33/115

Baseline characteristics

Age, Continuous
Age, Continuous(years)Panitumumab Plus FOLFIRI
Mean60.0 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab Plus FOLFIRI
Female41
Male75
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Panitumumab Plus FOLFIRI
White or Caucasian94
Black or African American13
Hispanic or Latino8
Asian1
Kirsten Rat Sarcoma Gene (KRAS) Mutation Status
Kirsten Rat Sarcoma Gene (KRAS) Mutation Status(participants)Panitumumab Plus FOLFIRI
Wild-type65
Mutant45
Unevaluable6
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Cohn AL, Shumaker GC, Khandelwal P, Smith DA, Neubauer MA, Mehta N, Richards D, Watkins DL, Zhang K, Yassine MR. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2011 Sep;10(3):171-7. doi: 10.1016/j.clcc.2011.03.022. Epub 2011 Apr 28. PubMed 21855038 ↗
  • Weeraratne D, Chen A, Pennucci JJ, Wu CY, Zhang K, Wright J, Perez-Ruixo JJ, Yang BB, Kaliyaperumal A, Gupta S, Swanson SJ, Chirmule N, Starcevic M. Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol. 2011 Nov 9;11:17. doi: 10.1186/1472-6904-11-17. PubMed 22070868 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Jan 2009 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 7 years 1 month after primary completion. A results delay was requested in Jul 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2006
First posted
Dec 14, 2006
Start
Nov 2006
Primary completionActual
Jan 2009
CompletionActual
Oct 2010
Results delay requested
Jul 20, 2010
Results first posted
Feb 15, 2016
Last update
Feb 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00411450
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 14, 2006
Start date
Nov 2006
Primary completion
Jan 2009
Completion
Oct 2010
Results posted
Feb 15, 2016
Last update
Feb 15, 2016

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion